α-干扰素加软坚散结汤抗慢性乙型肝炎肝纤维化及早期肝硬化的临床研究

Clinical Evaluation of Therapy Effects for Liver Fibrosis and Early Liver Cirrosis by Interferon a and Ruanjiae Sanjie Fluid in the Patients with Chronic Hepatitis B

目的:探讨慢性乙型肝炎肝纤维化及早期肝硬化的中西医结合疗法。方法:采用α-干扰素加中药软坚散结汤联合治疗经病理确诊的慢性乙型肝炎患者62例,并以同期64例慢性乙肝患者作对照,疗程均为6个月。结果:治疗组临床症状及体征明显改善,血清ALT、TBil、A/G、γ球蛋白(γ-GT)和肝纤维化指标水平明显降低,血清白蛋白(A)水平有不同程度升高(P<0.01或0.05);B超示肝内光点粗、Ⅲ级血管走行欠清和分布不均等异常声像图明显改善,与对照组比较差异有显著性意义(P<0.05)。此外,治疗组HBeAg转阴率为61.0％,明显优于对照组36.3％(P<0.01)。结论:α-扰素和中药软坚散结汤联合应用,对改善慢性乙型肝炎患者临床症状体征,促进肝功能复常,抗肝纤维增生和抑制乙肝病复制等有显著疗效。

Objective: To evaluate the therapy methods of the chronic hepatits B with liver fibrosis and early liver cirrhosis.Methods: 62 patients with liver fibrosis and early liver cirrhosis of chronic hepatitis B were treated by combine intef-iron- a with Ruanjian Sanjie fluid, and compared with 64 patients with chronic hepatitis B, the duration of treatment lasted 6 months.Results: Clinial symptoms, abnormal signs, serum alaine aminotransferase (ALT), bili rubin (Bil), γ-globulin (γ-G) and parameters of fibrosis level such as hyaluronic acid (HA), N-terminal propeptide of TypeⅢ (pⅢp) and laminin were greatly improved in treatment group than in compared group (P< 0.01 or 0.05); and albumin (A) was higher in teatment grorp than in compared group (P < 0.05 ) . Furthermore the intensity of hepatic ech. blood of the liver vessels and enlargement of the spleen were better in the B-mode ultrasound in treatment group than in compared group (P<0.05) .Conclusion: Application of interferon-a and Ruanjian Sanjie fluid for liver fibrosis and early liver cirrhosis is useful in the patients with chromic hepatiis B.